Keywords
Depression
Trigeminal neuralgia
Mental health
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify, through the literature, the main drugs used in the treatment of trigeminal neuralgia (TN) and the impact of this disease on the mental health of patients. Methods: This is an integrative review, in which articles published since 2019, in Portuguese and English, were analyzed. The research was carried out between August and September 2024, in the databases: PubMed, Web of Science and Sciencedirect. The descriptors were: anticonvulsants, depression, trigeminal neuralgia, mental health, and treatment. As a guiding question: what is the most commonly used anticonvulsant in trigeminal neuralgia and the main impacts on patients' mental health? Results: After applying the inclusion and exclusion criteria, it was identified that carbamazepine (CBZ) and oxcarbazepine (OXC) are the most commonly used drugs in the treatment of TN and with the most adverse effects. Studies have shown that other anticonvulsants can be used to complement therapy. As for the way that TN interferes with the mental health of patients, it was identified that it can generate disorders such as depression and anxiety. Final considerations: Oxcarbazepine and carbamazepine are first-line drugs for TN and can be replaced by drugs with fewer adverse effects. TN causes negative impacts on mental health, and psychological monitoring of patients is important.
References
ALKAZAZ A, et al. Efficacy of drugs for classical trigeminal neuralgia; statistical study comparative to gold-standard carbamazepine. Journal of Garmian University, SCAPAS Conferance, 2019; p. 194-200.
ARAYA EI, et al. Trigeminal neuralgia: basic and clinical aspects. Current neuropharmacology, 2020; p. 109-119.
BAUER M, et al. Clinical Depression and Anxiety Are Relieved by Microvascular Decompression in Patients with Trigeminal Neuralgia—A Prospective Patient-Reported Outcome Study. Journal of Clinical Medicine, 2024; p. 2329.
BENDTSEN L, et al. European Academy of Neurology guideline on trigeminal neuralgia. European journal of neurology, 2019; p. 831-849.
CHANG B, et al. Effects of depression and anxiety on microvascular decompression outcome for trigeminal neuralgia patients. World Neurosurgery, 2019; p. e556-e561.
DA CRUZ C, et al. Nevralgia do trigémio atípica: um caso clínico. Revista Portuguesa de Medicina Geral e Familiar, 2022; 38(4), 387-91.
DE MOURA CV, et al. Disponibilidade de informação à população sobre os principais fármacos utilizados para o tratamento da dor crônica. Anais da Faculdade de Medicina de Olinda, 2019; p. 25-32.
DI STEFANO G, et al. Real‐world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia. European journal of pain, 2021;25(5), 1064-1071.
DONERTAS-AYAZ B, et al. Locus coeruleus-noradrenergic modulation of trigeminal pain: Implications for trigeminal neuralgia and psychiatric comorbidities. Neurobiology of Pain, 2023; p. 100124.
FLORÊNCIO DSF, et al. A efetividade dos tratamentos não cirúrgicos na neuralgia do trigêmeo: um protocolo de overview. Revista CEFAC, 2022; p. e1822.
GUO M, et al. Safety and efficacy of carbamazepine in the treatment of trigeminal neuralgia: A metanalysis in biomedicine. Math Biosci Eng, 2024; p. 5335-59.
HSIEH B, et al. Levetiracetam in management of bilateral trigeminal neuralgia due to large glomus tumor case report. Cephalalgia Reports, 2021; p. 25158163211042389.
IQBAL S, et al. Efficacy of Carbamazepine and Oxcarbazepine for Treating Trigeminal Neuralgia. BMC Journal of Medical Sciences, 2022; p. 55-59.
KOLAKOWSKI L, et al. Interdisciplinary strategies for diagnosis and treatment of trigeminal neuralgia. Swiss Medical Weekly, 2024; p. 3460, 2024.
LAMBRU G, et al. Trigeminal neuralgia: a practical guide. Practical neurology, 2021; p. 392-402, 2021.
LIAO CC, et al. Long-term beneficial effects of acupuncture with reduced risk of depression development following trigeminal neuralgia: a nationwide population-based Cohort study. Neuropsychiatric Disease and Treatment, 2020; p. 2961-2973.
LUO Y, et al. A research on quality of life score (QOLS) of patients with trigeminal neuralgia (TN). Journal of infection and public health, 2019; p. 690-694.
LVSS, et al. Corticotropin-releasing hormone neurons control trigeminal neuralgia-induced anxiodepression via a hippocampus-to-prefrontal circuit. Science Advances, 2024; p. eadj4196, 2024.
MUÑOZ-VENDRELLA, et al. Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases. Cephalalgia, 2022; p. 1031-1038.
NADERI Y, et al. Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review. Clinical and Experimental Dental Research, 2024; 10(2), e882.
PAIKER S, et al. Eficáciaclínica da oxcarbazepinaemcomparação com a carbamazepinaemtermos de alívio da dor no tratamento da neuralgia dotrigêmeo. Annals of Punjab Medical College,2024; 18 (1), 36-41.
RADOŠ I. Treatment options for trigeminal neuralgia. Acta clinicaCroatica, 2022; p. 96-101.
SILVACC e da Silva JL. O uso da carbamazepina e da lamotrigina no tratamento da neuralgia do trigêmeo. RECIMA21-Revista Científica Multidisciplinar-ISSN 2675-6218, 2022; 3(10), e3102010-e3102010.
TANG X, et al. Rehabilitation therapy outside of the hospital via the Internet combined with suggestive psychological intervention in patients with trigeminal neuralgia. American Journal of Translational Research, 2021; p. 6837.
WIFFEN PJ, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane database of systematic reviews, 2014; n. 4.
ZAHER B, et al. Therapeutic management of carbamazepine's complications in front of essential trigeminal neuralgia. Advancesin OralandMaxillofacialSurgery, 2022; p. 100372.
ZHANG L, et al. Curcumin improves chronic pain induced depression through regulating serum metabolomics in a rat model of trigeminal neuralgia. Journal of Pain Research, 2020; 3479-3492.
ZIEGELERC, et al.Características e histórico natural da doença de dor facial idiopáticapersistente, neuralgia do trigêmeo e dor facial neuropática. Dor de cabeça: The Journal of Head and Face Pain, 2021; 61 (9), 1441